• Caffeine (1,3,7-trimethylpurine-2,6-dione) in Cancer and Met

  2026-06-11

  Caffeine, a well-characterized adenosine receptor antagonist, is unlocking new potential in cancer cell line inhibition and metabolic modulation across both in vitro and in vivo systems. This article delivers actionable workflow guidance, practical troubleshooting, and strategic insights for maximizing research value with APExBIO's high-purity caffeine.

• Biotin-HPDP in Redox Proteomics: Reversible Thiol Labeling U

  2026-06-10

  Explore the advanced use of Biotin-HPDP for reversible, thiol-specific protein labeling in redox proteomics. This deep dive highlights unique mechanistic insights and practical guidance for optimizing biotinylation in complex neurodegenerative research.

• MLN8237 (Alisertib): Data-Driven Solutions for Tumor Cell As

  2026-06-10

  This article provides scenario-based best practices for using MLN8237 (Alisertib) (SKU A4110) in cell viability, proliferation, and apoptosis studies. By addressing real-world workflow challenges and referencing quantitative data, researchers can optimize reproducibility and interpretative clarity in cancer biology assays with MLN8237.

• TAK-242 (Resatorvid): Precision TLR4 Inhibition in Sepsis Pa

  2026-06-09

  Explore the scientific foundations of TAK-242 (Resatorvid), a selective TLR4 inhibitor, with a focus on its pivotal role in modulating coagulation and inflammation in sepsis research. This article uniquely dissects mechanistic insights and practical protocol parameters, setting it apart from typical neuroinflammation-focused reviews.

• FXR-KLF11 Axis: CDCA Suppresses JAK2/STAT3 in CI-AKI Protect

  2026-06-09

  This study demonstrates that Chenodeoxycholic Acid (CDCA) activates the FXR-KLF11 pathway, leading to suppression of JAK2/STAT3 signaling and significant protection against contrast-induced acute kidney injury (CI-AKI) in preclinical models. Mechanistic insights reveal direct FXR-mediated transcriptional upregulation of KLF11, suggesting a targeted strategy for renal protection and advancing cholesterol metabolism research.

• Pepstatin A in Modern Assay Design: Beyond Classical Inhibit

  2026-06-08

  Explore how Pepstatin A, a benchmark aspartic protease inhibitor, is redefining assay precision in complex biological systems. This article uniquely dissects its integration into advanced RNA profiling and protease inhibition workflows, offering actionable insights for innovative biomedical research.

• TAI-1: Applied Workflows for Potent Hec1 Inhibitor Assays

  2026-06-08

  TAI-1 sets a new standard for small molecule Hec1 inhibitor research, enabling high-sensitivity, reproducible cancer cell assays with advanced mechanistic selectivity. Explore optimized protocols, troubleshooting strategies, and insights from the latest DNA damage research to drive breakthroughs in proliferation inhibition and apoptotic cell death induction.

• Flavone Glucoside Discovery in Scutellaria baicalensis: Stru

  2026-06-07

  The reference study isolated and characterized two novel flavone 2'-glucosides, alongside seven known phenolics including baicalin methyl ester, from Scutellaria baicalensis roots. This work advances structural understanding of flavonoid diversity in S. baicalensis and provides a foundation for translational studies on intestinal barrier protection and anti-inflammatory mechanisms.

• Ciprofloxacin in Genomic Resistance Mapping: Beyond Model Sy

  2026-06-06

  Explore Ciprofloxacin’s unique role as a fluoroquinolone antibiotic in dissecting the genomic transmission of resistance genes. This article delivers advanced insights for researchers, focusing on molecular epidemiology, assay design, and the practical impact of recent multidrug resistance findings.

• Small Molecule Antagonists Disrupt Sonic Hedgehog–Heparin Bi

  2026-06-05

  Lamson et al. performed a high-throughput screen to identify small molecules that antagonize the binding between Sonic hedgehog (Shh) and heparin, a key modulator in Hedgehog pathway signaling. The study's identification and mechanistic validation of novel antagonists clarify targeting opportunities at the ligand–glycan interface and offer refined tools for dissecting Hedgehog pathway function in development and disease.

• Allosteric Disruption of ERα by Mitoxantrone: Novel Breast C

  2026-06-05

  Wang et al. reveal that Mitoxantrone, beyond its established role as a DNA topoisomerase II inhibitor, targets the ERα DBD-LBD interface, inducing proteasomal degradation of both wild-type and therapy-resistant estrogen receptors. This discovery highlights a promising therapeutic approach to overcome resistance in luminal breast cancer models.

• Transmission of Carbapenemase Genes in CREC: Insights From G

  2026-06-04

  This study systematically characterizes carbapenemase-encoding genes (CEGs) and their transmission dynamics in carbapenem-resistant Enterobacter cloacae from eight hospitals in Guangdong, China. The findings highlight the prevalence of blaNDM-1 on plasmids, extensive horizontal gene transfer, and multidrug resistance, informing both local epidemiology and antimicrobial research strategies.

• (+)-Bicuculline: Technical Protocols for GABAA Antagonist Wo

  2026-06-04

  (+)-Bicuculline is a classical GABAA receptor antagonist utilized to dissect inhibitory neurotransmission and modulate synaptic NMDA receptor signaling in neuroscience research. It is not designed for diagnostic or clinical use and demands careful attention to solubility and storage for reproducible results. Researchers should follow explicit workflow and handling parameters to avoid common technical pitfalls.

• AMD-070 Hydrochloride: Advanced CXCR4 Antagonist Workflows

  2026-06-03

  AMD-070 hydrochloride (Mavorixafor hydrochloride) is a potent CXCR4 antagonist, uniquely positioned for translational anti-HIV and immunology research due to its high solubility and proven in vivo effects. This article details optimized experimental workflows, comparative advantages, and troubleshooting strategies that maximize reproducibility and insight with this advanced compound.

• CD44-Driven Metabolic Rewiring in IDH-Mutant AML: Therapeuti

  2026-06-03

  This study uncovers a crucial role for CD44 in sustaining NADPH production and oncometabolite (R)-2-hydroxyglutarate synthesis in IDH-mutant leukemia. Targeting the CD44-mediated metabolic pathway reveals a new therapeutic vulnerability, with significant implications for overcoming resistance to mutant IDH1 inhibitors in AML.

406 records 12/28 page Previous Next First page 上5页 1112131415 下5页 Last page